Compare The Coca-Cola Co K (KO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs BIO-TECHNE Corp — how do they compare? The Coca-Cola Co K trades at $81.87 (market cap $353.32B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: The Coca-Cola Co K is far larger — about 31.7× BIO-TECHNE Corp's market cap, and The Coca-Cola Co K pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| KO | TECH | |
|---|---|---|
Market Cap | $353.32B | $11.16B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $72.12 |
52-Week Low | $65.67 | $43.31 |
Enterprise Value | $383.39B | $11.24B |
Dividend Yield | 2.58% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.74, up 0.22% today, with a bearish technical signal but strong fundamentals including 27.8% net margin and consistent earnings beats. The stock shows robust profitability with ROE at 45.8% and positive cash flow trends, supported by a $0.53 quarterly dividend. Recent news highlights institutional buying and stable demand ahead of Q2 2026 earnings.
Outlook remains positive with a $90.67 consensus price target implying 11% upside, though risks include regional demand divergence and high debt. Analyst sentiment is bullish (60% Buy), but technical resistance near $83 may limit near-term gains. Long-term investors may find value in KO's dividend stability and brand strength.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
